Late last week Promore announced modifications of the Phase III study for PXL01. To mitigate delays, due to manufacturing issues of the investigational medicinal product, Promore intends to expand the number of clinical sites. The delayed start of the study into next year is negative news, but as long as the original plan keeps (topline results H1 2021), it does not affect our view of the investment case.